---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-267934"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:44:38.490915+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular announces positive interim 1.5-3.5 year data for 4D-150 in wet AMD; 79-92% injection reduction

## Summary
- Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.
- Phase 2b recently diagnosed subgroup (Phase 3 comparable): 92% reduction in mean supplemental injections vs aflibercept at 1.5 years.
- Phase 2b broad cohort: 82% reduction; Phase 1/2a severe recalcitrant: 79% reduction at 2 years.
- Safety: 2.8% (2/71) mild transient IOI within 28 weeks; no new IOI after 28 weeks; no hypotony, endophthalmitis, vasculitis.
- Consistent dose response favoring Phase 3 dose (3E10 vg/eye) over lower dose across all cohorts.

## SEC filing metadata
- accession: 0001193125-25-267934
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/0001193125-25-267934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/d280681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-267934
- JSON: https://secwatch.observer/filing/0001193125-25-267934.json
- Plain text: https://secwatch.observer/filing/0001193125-25-267934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.